KR101314952B1 - 비-단백질 안정화된 클로스트리디움계 독소 약제학적조성물 - Google Patents

비-단백질 안정화된 클로스트리디움계 독소 약제학적조성물 Download PDF

Info

Publication number
KR101314952B1
KR101314952B1 KR1020077028607A KR20077028607A KR101314952B1 KR 101314952 B1 KR101314952 B1 KR 101314952B1 KR 1020077028607 A KR1020077028607 A KR 1020077028607A KR 20077028607 A KR20077028607 A KR 20077028607A KR 101314952 B1 KR101314952 B1 KR 101314952B1
Authority
KR
South Korea
Prior art keywords
botulinum toxin
protein
toxin
pharmaceutical composition
botulinum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077028607A
Other languages
English (en)
Korean (ko)
Other versions
KR20080052510A (ko
Inventor
테렌스 제이. 헌트
Original Assignee
알러간, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37527018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101314952(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알러간, 인코포레이티드 filed Critical 알러간, 인코포레이티드
Publication of KR20080052510A publication Critical patent/KR20080052510A/ko
Application granted granted Critical
Publication of KR101314952B1 publication Critical patent/KR101314952B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020077028607A 2005-10-06 2006-10-04 비-단백질 안정화된 클로스트리디움계 독소 약제학적조성물 Expired - Fee Related KR101314952B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72512605P 2005-10-06 2005-10-06
US60/725,126 2005-10-06
US11/524,683 2006-09-21
US11/524,683 US8137677B2 (en) 2005-10-06 2006-09-21 Non-protein stabilized clostridial toxin pharmaceutical compositions
PCT/US2006/038913 WO2007041664A1 (en) 2005-10-06 2006-10-04 Non-protein stabilized clostridial toxin pharmaceutical compositions

Publications (2)

Publication Number Publication Date
KR20080052510A KR20080052510A (ko) 2008-06-11
KR101314952B1 true KR101314952B1 (ko) 2013-10-04

Family

ID=37527018

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077028607A Expired - Fee Related KR101314952B1 (ko) 2005-10-06 2006-10-04 비-단백질 안정화된 클로스트리디움계 독소 약제학적조성물

Country Status (16)

Country Link
US (5) US8137677B2 (enExample)
EP (2) EP1931306B2 (enExample)
JP (4) JP5140595B2 (enExample)
KR (1) KR101314952B1 (enExample)
AU (1) AU2006299366B2 (enExample)
CA (1) CA2602926C (enExample)
CY (1) CY1117727T1 (enExample)
DK (1) DK2679217T3 (enExample)
ES (1) ES2580010T3 (enExample)
HU (1) HUE027810T2 (enExample)
MX (1) MX2007012062A (enExample)
NZ (1) NZ562033A (enExample)
PL (1) PL2679217T3 (enExample)
PT (1) PT2679217T (enExample)
SI (1) SI2679217T1 (enExample)
WO (1) WO2007041664A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
AU2005251676B2 (en) * 2004-03-03 2011-09-29 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
BRPI0513850A (pt) * 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
BRPI0608249A2 (pt) * 2005-03-03 2009-12-08 Revance Therapeutics Inc formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
CN103315954A (zh) 2005-07-18 2013-09-25 麻萨诸塞州洛厄尔大学 制备与使用纳米乳剂的组合物和方法
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
TR201901443T4 (tr) 2005-12-01 2019-02-21 Univ Massachusetts Lowell Botulinum nanoemülsiyonları.
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
CA2671133C (en) 2006-12-01 2015-11-24 Anterios, Inc. Peptide nanoparticles and uses therefor
EP2494958A1 (en) 2006-12-01 2012-09-05 Anterios, Inc. Amphiphilic Entity Nanoparticles
US10016451B2 (en) 2007-05-31 2018-07-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
CA2690773C (en) * 2007-07-10 2013-09-17 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
WO2009035707A1 (en) 2007-09-14 2009-03-19 Acambis Inc. Pharmaceutical compositions containing clostridium difficile toxoids a and b
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
KR20160103551A (ko) * 2008-12-10 2016-09-01 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
HRP20180739T1 (hr) 2008-12-31 2018-06-29 Revance Therapeutics, Inc. Injekcijske formulacije botulinskog toksina
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
EP2445509B1 (en) 2009-06-24 2016-11-30 Charles N.S. Soparkar Zinc supplementation to increase responsiveness to metalloprotease therapy
CA2766521C (en) 2009-06-25 2020-07-21 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
EP2504878A4 (en) * 2009-11-09 2014-01-08 Enerdel Inc SCALABLE BATTERY MODULE
EP2627318B1 (en) 2010-10-12 2017-08-16 Merz Pharma GmbH & Co. KGaA Formulation suitable for stabilizing proteins, which is free of mammalian excipients
BR112013025256B1 (pt) * 2011-03-31 2022-01-18 Medy-Tox Inc Preparação liofilizada farmacêutica
KR20140147950A (ko) * 2013-06-20 2014-12-31 서울대학교산학협력단 필러와 보틀리눔 독소를 포함하는 피부 주름, 노화 개선 또는 신경근육 관련 질환 치료용 조성물
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
US9403941B2 (en) 2014-07-07 2016-08-02 Mast Therapeutics, Inc. Poloxamer composition free of long circulating material and methods for production and uses thereof
JP6798993B2 (ja) 2014-12-23 2020-12-09 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ボツリヌス毒素プレフィルド容器
WO2017179775A1 (en) * 2016-04-12 2017-10-19 Hugel Inc. Microstructure formulation techniques for botulinum toxin
HUE046449T2 (hu) 2016-09-13 2020-03-30 Allergan Inc Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents
EP3470054B1 (en) * 2017-10-11 2023-09-20 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
US11149262B2 (en) 2017-12-20 2021-10-19 Alleergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation
US20200108129A1 (en) * 2018-09-13 2020-04-09 Allergan, Inc. Clostridial toxin - hyaluronic acid compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030066330A (ko) * 2000-06-02 2003-08-09 알레간 인코포레이티드 신경독 임플란트

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE229810T1 (de) * 1985-07-09 1987-11-05 Quadrant Bioresources Ltd., Soulbury, Leighton Buzzard, Bedfordshire Beschuetzung von proteinen und aehnlichem.
DE3603444A1 (de) * 1986-02-05 1987-08-06 Thomae Gmbh Dr K Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha
US5215743A (en) * 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
CA2138020C (en) 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5556771A (en) * 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
DE69627963T2 (de) 1995-06-06 2004-03-04 Pearce, L. Bruce, Cambridge Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen
JPH0952844A (ja) * 1995-08-10 1997-02-25 Amano Pharmaceut Co Ltd 酵素含有内服液剤
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
CN1073626C (zh) 1997-10-18 2001-10-24 卫生部兰州生物制品研究所 A型肉毒结晶毒素的生产工艺及生产该毒素所需的冻干保护液
CA2319113A1 (en) * 1998-01-26 1999-07-29 University Of Massachusetts Biologically active hemagglutinin from type a clostridium botulinum and methods of use
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
IL126182A0 (en) 1998-09-11 1999-05-09 Nun Yehoshua Ben Cryosurgical instrument
US20050147690A1 (en) * 1998-09-25 2005-07-07 Masters David B. Biocompatible protein particles, particle devices and methods thereof
IL149778A0 (en) 1999-11-22 2002-11-10 Universal Preservation Technologies Inc Preservation of sensitive biological material
CA2494241C (en) * 2000-02-08 2011-06-14 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6653062B1 (en) * 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040161776A1 (en) * 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
PL207018B1 (pl) * 2002-06-21 2010-10-29 Novo Nordisk Helth Care Ag Kompozycja farmaceutyczna, sposób przygotowania stabilnego polipeptydu czynnika VII i zastosowanie polipeptydu czynnika VII
AU2003287640A1 (en) * 2002-11-12 2004-06-03 Collegium Pharmaceutical, Inc. Inertial drug delivery system
US20060002862A1 (en) * 2002-12-17 2006-01-05 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
MXPA05006690A (es) 2002-12-20 2006-02-17 Botulinum Toxin Res Ass Inc Composiciones farmaceuticas de toxina botulinica mejoradas.
US20040204471A1 (en) * 2003-03-20 2004-10-14 Pharmacia Corporation Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US8153591B2 (en) * 2003-08-26 2012-04-10 Gel-Del Technologies, Inc. Protein biomaterials and biocoacervates and methods of making and using thereof
US8529939B2 (en) * 2003-12-08 2013-09-10 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
US20050214325A1 (en) * 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
AU2005256322C1 (en) * 2004-06-28 2011-07-07 Veloxis Pharmaceuticals, Inc. Porous tablets as carriers for liquid formulations
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
BRPI0513850A (pt) * 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
EP2813239B1 (en) * 2004-08-04 2017-03-22 Ipsen Biopharm Limited Pharmaceutical composition containing botulinum neurotoxin A2
PL1797109T3 (pl) * 2004-09-09 2016-11-30 Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania
US9504658B2 (en) * 2004-11-09 2016-11-29 Board Of Regents, The University Of Texas System Stabilized HME composition with small drug particles
SI1954308T1 (sl) * 2005-09-16 2011-12-30 Merial Ltd Stabilizatorji za liofilizirana cepiva
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
AU2008231072B2 (en) * 2007-03-22 2013-08-01 The Regents Of The University Of Colorado Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
EP1985276A1 (en) * 2007-04-26 2008-10-29 Merz Pharma GmbH & Co. KGaA Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy
US10369204B2 (en) * 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
ES2732150T3 (es) * 2010-01-20 2019-11-20 Urogen Pharma Ltd Material y método para tratar cavidades internas
EP2627318B1 (en) * 2010-10-12 2017-08-16 Merz Pharma GmbH & Co. KGaA Formulation suitable for stabilizing proteins, which is free of mammalian excipients

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030066330A (ko) * 2000-06-02 2003-08-09 알레간 인코포레이티드 신경독 임플란트

Also Published As

Publication number Publication date
DK2679217T3 (en) 2016-07-25
JP2012197320A (ja) 2012-10-18
US8642047B2 (en) 2014-02-04
AU2006299366A1 (en) 2007-04-12
JP5758856B2 (ja) 2015-08-05
ES2580010T3 (es) 2016-08-18
NZ562033A (en) 2011-12-22
EP2679217A1 (en) 2014-01-01
AU2006299366B2 (en) 2012-01-12
SI2679217T1 (sl) 2016-08-31
JP5140595B2 (ja) 2013-02-06
US20120141619A1 (en) 2012-06-07
JP6235176B2 (ja) 2017-11-22
EP1931306A1 (en) 2008-06-18
MX2007012062A (es) 2007-12-04
WO2007041664A1 (en) 2007-04-12
CA2602926C (en) 2010-12-21
EP1931306B2 (en) 2021-09-22
US20100279953A1 (en) 2010-11-04
HK1192710A1 (en) 2014-08-29
JP2009511485A (ja) 2009-03-19
PT2679217T (pt) 2016-07-15
HUE027810T2 (en) 2016-11-28
JP2017088611A (ja) 2017-05-25
EP2679217B1 (en) 2016-04-06
CA2602926A1 (en) 2007-04-12
US8137677B2 (en) 2012-03-20
PL2679217T3 (pl) 2016-11-30
EP1931306B1 (en) 2013-07-31
KR20080052510A (ko) 2008-06-11
CY1117727T1 (el) 2017-05-17
US20200330564A1 (en) 2020-10-22
JP2014139229A (ja) 2014-07-31
US20240226252A1 (en) 2024-07-11
US20140112908A1 (en) 2014-04-24

Similar Documents

Publication Publication Date Title
KR101314952B1 (ko) 비-단백질 안정화된 클로스트리디움계 독소 약제학적조성물
JP5690785B2 (ja) 改良されたボツリヌス毒素組成物
AU2016204034B2 (en) Non-protein stabilized clostridial toxin pharmaceutical compositions
AU2013202329B2 (en) Non-protein stabilized clostridial toxin pharmaceutical compositions
AU2012202088B2 (en) Non-protein stabilized clostridial toxin pharmaceutical compositions
BRPI0613001B1 (pt) Composições farmacêuticas de toxina clostrídica estabilizada por uma não-proteína
HK1179874B (en) Improved botulinum toxin compositions

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160909

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170913

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20180906

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240928

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240928